Budesonide treatment for collagenous colitis: A randomized, double-blind, placebo-controlled, multicenter trial

Macroscopic Findings in Microscopic Colitis: Two Case Reports and a Review of Literature

“…Clinical response was also matched by histologic remission in these studies [22,23]. The mean time to induce remission in patients with collagenous colitis was found to be 7 to 13 days [23]. The overall response may be expected for up to 81% of MC patients.…”

“…Data from randomized trials indicates that Budesonide (9mg up to 8 weeks) increased the probability of experiencing clinical remission by 152% after 6 to 8 months of follow-up (RR, 2.52; 95% CI, 1.45-4.4). Clinical response was also matched by histologic remission in these studies [22,23]. The mean time to induce remission in patients with collagenous colitis was found to be 7 to 13 days [23].…”

Collagenous colitis in children and adolescents: study of 7 cases and literature review

“…These findings are consistent with the previously reported intraepithelial lymphocytosis in terminal ileum in adult patients with CC. 26,27 While clinical trials have shown the efficacy of budesonide treatment in adult patients with CC, [28][29][30][31][32] treatment for children appears to be largely empiric with various agents (Table 1). Overall, sulfasalazine, mesalazine, and cholestyramine were either ineffective or only partially effective.…”

Colitis microscópica: Un diagnóstico a tener en cuenta en caso de diarrea secretora

“…También se han comunicado remisiones clínicas con colestiramina, reivindicando así un hipotético papel de los ácidos biliares, cuya malabsorción podría estar implicada en la patogenia de la enfermedad (27). Una buena opción terapéutica son los corticoides, sobre todo la budesonida por vía oral con la cual, en un estudio reciente, (con dosis de 9 mg al día durante 6 semanas), se consiguió una rápida remisión tanto clínica como histológica en pacientes con colitis colágena, minimizando los efectos secundarios achacados a otros corticoides (28). Los aminosalicilatos como la sulfasalazina (29), (a dosis de 2-3 g al día) olsalazina (30) y sobre todo la mesalazina (31) (a dosis de 1,2-4 g al día) se han usado también con gran éxito; lo cual viene a reforzar la referida similitud de esta entidad clínica con la enfermedad inflamatoria intestinal.…”